Iterum projects $5M-$15M in 2026 ORLYNVAH sales while advancing streamlined commercialization and payer access
Source: SeekingAlpha
2025-11-14 11:12:11 ET
More on Iterum Therapeutics
- Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript
- Iterum Therapeutics Non-GAAP EPS of -$0.16, revenue of $0.39M
- Seeking Alpha’s Quant Rating on Iterum Therapeutics
- Historical earnings data for Iterum Therapeutics
- Financial information for Iterum Therapeutics
Read the full article on Seeking Alpha
For further details see:
Iterum projects $5M–$15M in 2026 ORLYNVAH sales while advancing streamlined commercialization and payer access
Iterum Therapeutics plc
NASDAQ: ITRM
ITRM Trading
2.15% G/L:
$0.1619 Last:
368,001 Volume:
$0.1648 Open:
ITRM Latest News
ITRM Stock Data
$15,988,461
51,778,499
0.46%
14
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 1
